Viatris (VTRS) EBITDA Margin Growth (1y) (2020 - 2026)
Viatris (VTRS) EBITDA Margin Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 304.00 |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | -157.00 |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -5,330.00 |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | -650.00 |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 8,630.00 |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 1,962.00 |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 111.00 |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 31.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8,630.00 |
| Dec 31, 2025 | 1.00 |
| Sep 30, 2025 | -127.00 |
| Jun 30, 2025 | 1,287.00 |
| Mar 31, 2025 | -9,413.00 |
| Dec 31, 2024 | 680.00 |
| Sep 30, 2024 | -546.00 |
| Jun 30, 2024 | -1,576.00 |
| Mar 31, 2024 | -516.00 |
| Dec 31, 2023 | -682.00 |
| Sep 30, 2023 | -229.00 |
| Jun 30, 2023 | -394.00 |
| Mar 31, 2023 | -621.00 |
| Dec 31, 2022 | -338.00 |
| Sep 30, 2022 | 586.00 |
| Jun 30, 2022 | 1,441.00 |
| Mar 31, 2022 | 2,298.00 |
| Dec 31, 2021 | 2,255.00 |
| Mar 31, 2021 | -1,319.00 |
| Dec 31, 2020 | -3,022.00 |